STOCK TITAN
  1. Home
  2. News
  3. BCTXW

BriaCell Therapeutics Corp - BCTXW STOCK NEWS

Welcome to our dedicated news page for BriaCell Therapeutics (Ticker: BCTXW), a resource for investors and traders seeking the latest updates and insights on BriaCell Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BriaCell Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BriaCell Therapeutics's position in the market.

News
BriaCell Announces Oral and Poster Presentations at ASCO 2024
Rhea-AI Summary
BriaCell Therapeutics Corp. announces oral and poster presentations at ASCO 2024 by Mayo Clinic Professor Saranya Chumsri on clinical data of Bria-IMT™ in advanced metastatic breast cancer. Two posters feature collaborations with prominent medical professionals in pivotal Phase 3 study and clinical data of Bria-IMT™ in patients who failed ADCs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.6%
Tags
none
-
News
BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer
Rhea-AI Summary
BriaCell Therapeutics Corp. reports strong anti-cancer activity of Bria-OTS+™ and Bria-PROS+™ immunotherapies in breast and prostate cancer patients based on preclinical data presented at AACR 2024. The novel mechanisms of action show enhanced immune responses and activation of key immune system components, potentially leading to potent and long-lasting anti-cancer effects. The next-generation platforms aim to provide personalized, off-the-shelf, and ready-to-use therapies with improved efficacy and safety profiles.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.21%
Tags
none
-
News
BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR
Rhea-AI Summary
BriaCell Therapeutics Corp. presents positive clinical data for Bria-IMT™ at AACR Annual Meeting, showcasing significant potential in managing CNS metastatic disease in advanced breast cancer. With a PFS of 4.2 months, clinical benefit rate of 56%, and 71% iORR, the findings reinforce the clinical efficacy of Bria-IMT™ in patients resistant to ADCs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.73%
Tags
none
News
BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies
Rhea-AI Summary
BriaCell Therapeutics Corp. signs an agreement with a leading cancer treatment group to advance the clinical development of Bria-OTS+ and Bria-PROS+, its novel personalized cancer vaccines. The collaboration with Dr. Paula Pohlmann from MD Anderson Cancer Center marks a significant milestone in BriaCell's mission to revolutionize cancer care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.05%
Tags
clinical trial
-
News
BriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis and Antibody-Drug Conjugate (ADC) Resistant Breast Cancer at the 2024 AACR Conference
Rhea-AI Summary
BriaCell Therapeutics Corp. announces the presentation of three posters at the 2024 AACR Annual Meeting, showcasing the efficacy and safety of their immunotherapies in cancer care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.24%
Tags
conferences clinical trial
-
News
BriaCell Provides Update on Alleged Illegal Trading of Public Securities
Rhea-AI Summary
BriaCell Therapeutics Corp. updates on the investigation of alleged illegal trading activity of its securities by filing complaints with FINRA and CIRO after identifying significant settlement share imbalances.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.57%
Tags
none
News
BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case
Rhea-AI Summary
BriaCell Therapeutics Corp. reports a preliminary disease control rate of 61% in evaluable Phase 2 advanced breast cancer patients treated with BriaCell’s Bria-IMT™ regimen in their open pivotal Phase 3 study. Additionally, a disease control rate of 50% was observed in patients who had failed prior antibody-drug conjugate (ADC) therapy. A notable responder who had failed 4 prior therapies, including ADC therapy with a metastatic liver tumor, saw significant improvement following BriaCell treatment. The company is encouraged by the clinical benefits observed and looks forward to sharing additional clinical data in the coming months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.83%
Tags
clinical trial
-
News
Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing
Rhea-AI Summary
BriaCell Therapeutics Corp. announces the initiation of Good Manufacturing Practice (GMP) manufacturing of its lead candidate for treating prostate cancer, Bria-Pros+. The company's next generation personalized immunotherapy platform, Bria-Pros+, is capable of activating multiple types of immune cells, including helper T cells, cytotoxic (killer) T cells, and natural killer cells. This represents a major milestone for BriaCell, as GMP manufacturing will provide clinical supplies for planned clinical trial use.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.34%
Tags
none
-
News
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
Rhea-AI Summary
BriaCell Therapeutics Corp. announces the results of its annual general meeting of shareholders, with an overwhelming vote in favor of all proposed resolutions. The meeting saw a total of 5,375,071 common shares voted, representing 33.63% of the Company's issued and outstanding Common Shares. Shareholders voted in favor of re-appointing MNP LLP as auditors and authorizing the directors' remuneration, as well as the election of seven directors. The formal report on voting results will be filed on the Company's SEDAR+ profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.19%
Tags
none
News
BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with “Eye-Bulging” Metastatic Breast Cancer
Rhea-AI Summary
BriaCell Therapeutics Corp. (BCTX) reports significant reduction in metastatic breast cancer tumor behind the eye after 3 cycles of Bria-IMT™ combination regimen. The patient had failed 7 prior regimens, including antibody-drug conjugate therapy, and experienced reduced proptosis and ocular pain. Bria-IMT™ showed robust anti-tumor activity in difficult-to-reach tumors, with a 71% intracranial objective response rate in breast cancer patients with CNS metastases. The pivotal Phase 3 study in advanced breast cancer is ongoing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.6%
Tags
none
Stock BCTXW logo
BriaCell Therapeutics Corp

Nasdaq:BCTXW

BCTXW Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

BCTXW Stock Data

11.64M
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Canada
West Vancouver

About BCTXW

briacell therapeutics corp immunotherapy approaches to cancer management briacell is a los angeles headquartered biotechnology company focused on immunotherapy treatments for cancer management. to date, the company has been successful in developing its patented "briavax" vaccine and implementing two compelling fda phase-i studies with late-stage breast cancer patients, demonstrating unique and unprecedented results. briacell is focused on aggressively moving towards launching its next clinical trial, a phase-i/ii study, in order to apply its vaccine to a larger number of breast cancer patients and effectively progress its technology along the value chain. while the current corporate focus is breast cancer, the company has an eye towards potentially applying its vaccine technology to certain other cancer types as well.